BPC-157: What Lakeland Readers Should Know

BPC-157 is one of the most talked-about peptides for injury recovery, and one of the least tested in people. This page explains what the research does and does not show, and where its regulatory status stood in November 2026. It is general information, not advice for your situation.

What it is and how it works

BPC stands for “body protection compound.” BPC-157 is a lab-made chain of 15 amino acids, the building blocks of proteins. Researchers first described it in the early 1990s as a piece of a larger protein found in human stomach juice.¹ The product sold today is made in a lab. It is not taken from the body.

Rat and cell studies suggest it may turn up growth signals, help new blood vessels form and lower inflammation signals.² But FDA’s 2026 review said the molecules BPC-157 acts on “have not been identified” and that how it works remains “poorly understood.”¹

BPC-157 is marketed as injections, capsules, oral and nasal sprays, and in blends with another peptide, TB-500. Some clinics call it a “wolverine compound” and promote it for gut, joint, tendon, ligament and bone healing.¹

What the research shows (and where evidence is weak)

Most BPC-157 research has been done in rats. Much of it comes from one research group in Zagreb, Croatia. A 2025 critique reported that more than 80% of BPC-157 papers list one of two researchers from that group as first or senior author. It said outside labs have added “only a handful” of short lab or rodent studies.³ Findings that independent teams have not repeated are less reliable.

A 2025 systematic review (a study that gathers all the published research on a question) looked at BPC-157 for muscle, tendon, ligament and bone injuries. Of 36 studies, 35 were in animals or the lab and only 1 was in people. The authors rated the evidence at the lowest levels. They found no study that tracked side effects in humans.²

FDA’s own review searched the medical literature through December 2025. It found only five human studies in total, all small and short:¹

• Bowel inflammation (ulcerative colitis). The only randomized trial (people assigned by chance to the drug or a dummy treatment), from 2005, was published only as a short meeting abstract. FDA called its data “inadequate.”
• Knee pain. A phone survey of 16 patients at a private Florida clinic, with no comparison group and no standard measurement tools. Most said their pain improved.⁴
• Bladder pain (interstitial cystitis). A study of 12 women at a private clinic, with no comparison group.⁵
• IV infusion. A safety test in 2 people.⁶
• Healthy volunteers. An early safety study using an enema.

The knee, bladder and IV reports all came from Florida clinics.¹

Key gaps:

• Not the forms people buy. No published human study used the under-the-skin, oral or nasal forms commonly sold.¹
• Unknown absorption. No one has measured how the human body absorbs or clears BPC-157 by those routes. In animals it leaves the blood within minutes.¹
• No finished trials. The only registered human trial, a small early study of tablets in Mexico, has posted no results.¹
• Unknown long-term safety. No study has followed people using it for months or years.

This does not prove BPC-157 does nothing. It means there is not enough good human evidence to know what it does in people.

FDA and regulatory status

Not approved. BPC-157 is not approved as a medicine in the United States or any other country, according to FDA’s May 2026 review.¹

FDA’s safety-concern list. BPC-157 was on FDA’s “Category 2” list of bulk ingredients that may pose significant safety risks in compounding. By April 22, 2026, the nominations were withdrawn; FDA still lists its safety concerns. These include possible immune reactions, impurities and little safety information for the routes proposed.⁷

FDA review and advisory vote. Pharmacies that mix their own medicines (compounding) can use an ingredient like BPC-157 only if it is on a list called the 503A bulks list. In May 2026, FDA’s scientists recommended against adding it. They pointed to poor product characterization, missing safety data, weak evidence for ulcerative colitis and the approved colitis drugs that already exist.¹ An FDA advisory committee narrowly voted in July 2026 to recommend adding BPC-157; FDA’s own reviewers had recommended against it, and the vote is not binding. The vote was reported as 8–6 with 1 abstention, and it covered only ulcerative colitis.⁸⁹ FDA has posted no minutes.¹⁰ Adding a substance to the list requires formal rulemaking.⁹

2026 HHS draft policy. According to law-firm summaries of the draft policy, it covers six peptides: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax.¹¹¹² As of 13 Nov 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding these peptides in certain forms.¹³ This is not FDA approval, and FDA has not added them to its official list.

The same summaries say the BPC-157 forms named are injections, oral and topical products. Conditions they describe include an FDA-registered ingredient source, a single active ingredient, documented absorption in people for oral products and a patient-specific prescription.¹¹¹² The policy names state-licensed pharmacies, federal facilities and licensed physicians, not online “research” sellers.¹³ As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.¹³

“Research use only” products. FDA’s review found BPC-157 and BPC-157/TB-500 blends sold online “for research purposes only.”¹ These are not made or checked as medicines. Read more in our guides to research chemical peptide risks and Florida peptide rules.

Sport. The World Anti-Doping Agency (WADA) bans BPC-157 at all times, under class S0 (non-approved substances) on its 2026 list.¹⁴

Common side effects and safety

• Small human studies. No serious side effects were reported, but FDA said safety tracking in most of the studies was unclear. Headache and gas were the most common complaints after enemas.¹
• Reports to FDA. FDA’s adverse-event database held 3 reports through December 2025, all after injections: an injection-site reaction; shortness of breath leading to an emergency-room visit; and skin and gum darkening that returned on reuse of a “research purposes only” BPC-157/TB-500 blend. FDA said it is unclear whether BPC-157 caused these.¹
• Animal findings. In 28-day studies in rats and dogs, BPC-157 was linked to changes in blood-clotting tests and liver-related blood markers. No cancer-risk studies have been done.¹
• Product quality. FDA is concerned about immune reactions (especially with injected and nasal forms), clumping of the peptide, impurities and uncertain product identity. It called BPC-157 “not well-characterized.”¹
• A theoretical cancer question. Because BPC-157 may promote blood vessel growth, critics say it could in theory help tumors grow. No studies show this either way, and the lead research group disputes the concern.³

If you have used BPC-157 and notice any symptom that worries you, tell a licensed provider.

Typical cost range

There is no reliable price data. BPC-157 is not an approved product, so it has no official list price, and no published cost analysis was found. Cost depends on the source, the form, and clinic visit or lab fees. Prices vary between clinics and pharmacies. Ask any provider for a written price breakdown before you start.

Our Polk County cost guide covers what to ask about pricing.

Questions to ask a provider

• Where does your BPC-157 come from, and which state-licensed pharmacy makes it?
• Does the product meet the conditions in the current HHS policy, and has that policy changed since November 2026?
• What human evidence supports using it for my problem?
• Which better-studied options, such as physical therapy or FDA-approved medicines, should I try first?
• Is it a single ingredient, or a blend with TB-500?
• What side effects should I watch for, and how do I reach you?
• How will we decide whether it is helping, and when to stop?
• What is the total cost, and what does it include?

See also how to vet a peptide clinic.